Detail

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated brands to CHEPLAPHARM. This is CHEPLAPHARM’s first acquisition of another well-known branded global product in 2019.

 

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated brands to CHEPLAPHARM. This is CHEPLAPHARM’s first acquisition of another well-known branded global product in 2019.

Ruud Dobber, Executive Vice President at AstraZeneca: “We already have an excellent relationship with CHEPLAPHARM, whose strong European presence and global distribution network will help ensure continued patient access to LOSEC®.”
“This agreement strengthens our relationship with AstraZeneca even further“, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Additionally, it matches perfectly with our internationally oriented business strategy, as CHEPLAPHARM can realize and further develop its ambitious growth strategy in the respective territories by enhancing the diversification of the country portfolios. Furthermore, this investment already contributes a significant part to our operating income in the fourth quarter of 2019.”

About LOSEC®
LOSEC® is a proton pump inhibitor discovered and developed by AstraZeneca, which helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. It has a number of approved indications and is commonly prescribed for patients with gastro oesophageal reflux disease.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com

*m/w/d
Back